key: cord-1053520-rq84n5v2
authors: Ma, Kevin C; Hale, Jaime E; Grad, Yonatan H; Alter, Galit; Luzuriaga, Katherine; Eaton, Roger B; Fischinger, Stephanie; Kaur, Devinder; Brody, Robin; Siddiqui, Sameed M; Leach, Dylan; Brown, Catherine M; Klevens, R Monina; Madoff, Lawrence; Comeau, Anne Marie
title: Trends in SARS-CoV-2 seroprevalence in Massachusetts estimated from newborn screening specimens
date: 2022-02-25
journal: Clin Infect Dis
DOI: 10.1093/cid/ciac158
sha: dc2fadf4a7f60415357fb1a7fc18145531a422a2
doc_id: 1053520
cord_uid: rq84n5v2

BACKGROUND: Estimating the cumulative incidence of SARS-CoV-2 is essential for setting public health policies. We leveraged de-identified Massachusetts newborn screening specimens to generate an accessible, retrospective source of maternal antibodies for estimating statewide SARS-CoV-2 seroprevalence in a non-test-seeking population. METHODS: We analyzed 72,117 newborn dried blood spots collected from November 2019 through December 2020, representing 337 towns and cities across Massachusetts. Seroprevalence was estimated for the general Massachusetts population after correcting for imperfect test specificity and nonrepresentative sampling using Bayesian multilevel regression and poststratification. RESULTS: Statewide seroprevalence was estimated to be 0.03% (90% credible interval (CI) [0.00, 0.11]) in November 2019 and rose to 1.47% (90% CI [1.00, 2.13]) by May 2020, following sustained SARS-CoV-2 transmission in the spring. Seroprevalence plateaued from May onwards, reaching 2.15% (90% CI [1.56, 2.98]) in December 2020. Seroprevalence varied substantially by community and was particularly associated with community percent non-Hispanic Black (β = 0.024, 90% CI [0.004, 0.044]); i.e., a 10% increase in community percent non-Hispanic Black was associated with a 27% higher odds of seropositivity. Seroprevalence estimates had good concordance with reported case counts and wastewater surveillance for most of 2020, prior to the resurgence of transmission in winter. CONCLUSIONS: Cumulative incidence of SARS-CoV-2 protective antibody in Massachusetts was low as of December 2020, indicating that a substantial fraction of the population was still susceptible. Maternal seroprevalence data from newborn screening can inform longitudinal trends and identify cities and towns at highest risk, particularly in settings where widespread diagnostic testing is unavailable.

Disease surveillance networks operate at multiple levels of government and healthcare, yet monitoring for outbreaks of new diseases remains a challenge. There are few material sources of information with limited cohort bias available to address questions about the frequency and distribution of a new infectious agent within populations. States' newborn screening (NBS) programs are such a resource: they collect and test infant dried blood spot (DBS) specimens at centralized clinical laboratories for markers of an ever-expanding panel of treatable disorders to inform timely care. Such programs comprise high-throughput laboratory testing with community outreach, operate under state authority, and maintain secure electronic and specimen records. Importantly, NBS-DBS infant specimens contain maternal IgG antibodies that cross the placenta and that reflect maternal exposure to infectious agents. The use of NBS to measure the seroprevalence of an emerging infectious disease was pioneered in the late 1980s for HIV [1] and adopted by a majority of states [2] .

This framework offers advantages for monitoring infections by new agents -such as SARS-CoV-2 -in the absence of symptomatic disease, particularly when diagnostic testing is limited in the initial stages of the pandemic, leading to uncertainty about the true infection burden. Many critical questions about SARS-CoV-2 infection are important to answer to inform public health responses to the pandemic: What proportion of our population has been exposed? How is exposure geographically distributed? Are the rates of exposure increasing in some populations faster than in others? What are the characteristics of those who become infected? Using data generated from NBS specimens, we report findings that address these questions from a survey of SARS-CoV-2 seroprevalence in childbearing women in Massachusetts.

Study population. Women who were residents of Massachusetts, gave birth in Massachusetts and whose infants' DBS specimens had completed routine newborn screening met study surveillance inclusion criteria with the DBS specimens serving as surrogates for the women. A control group was pre-defined to be those DBS arriving at the newborn screening program in March of 2019 and the study group was defined as those DBS arriving from November 4, 2019 through December 31, 2020. The following inclusion-exclusion criteria were applied: only one DBS specimen per infant and only one DBS specimen from each multiples' birth was included. All specimens of infants >30 days of age at time of specimen, all DBS of infants transfused within 48 hours, all specimens determined to be "unsatisfactory" quality for NBS, and all specimens from mothers who opted out of providing data for research were excluded.

The Institutional Review Boards of the Massachusetts Department of Public Health and the UMass Chan Medical School approved waivers of consent for the de-identified public health surveillance.

Antibody testing optimization. Human monoclonal IgG antibody cross reactive to SARS-CoV-2 was prepared from CR3022 variable genes expressed from plasmids, as described previously for other SARS-CoV-2 antibodies [3] . The receptor-binding domain (RBD) of the Spike protein used as ELISA Ag was expressed using HEK-293F cells and prepared as follows: a plasmid containing His-tagged RBD M a n u s c r i p t was transiently transfected in HEK-293F cells using PEI. The expressed protein was extracted and purified with Ni-NTA resin and stored at -80C until use. IgG antibodies specific to the RBD protein were detected in eluates from DBSs residual to the Massachusetts newborn screening program, by an adaptation of a previously described ELISA designed for serum [4] . Details of the protocol used can be found in the Supplementary Methods.

To determine positive and negative interpretations, we used a Plate-specific cutoff calculation using standard deviations (SD) above the mean of the replicates' average IgG concentration in a two-step process. In the first step, the mean and two SD were calculated for each plate. In the second step, any specimens with a concentration greater than or equal to two standard deviations above the plate mean from the first step were excluded from the calculation of the second mean and standard deviation (mean and SD of presumed negative samples). For Laboratory 1 (384-well assays), any specimen with a µg/mL result that was 5.3 SD above the second cycle mean was interpreted as positive. For laboratories 2 and 3 (96 well assays), any specimen with a µg/mL result that was 3.3 SD above the second cycle mean was interpreted as positive.

Inhibition assay. The inhibition assay was performed in the same manner as the standard IgG antibody analysis, with the following exceptions. Concentrated RBD diluted in dilution buffer was pre-mixed with DBS eluates so that the final dilution of the DBS eluates was identical to that used in the standard assay (1:4), and the final dilution of RBD was 1 µg/ml. This mixture was incubated for 30 minutes at RT, and 100 µl of the inhibited mixture was added to ELISA wells in duplicate. Uninhibited wells were also tested in duplicate, replacing the concentrated RBD with diluent alone. Percent inhibition was expressed as 100 * (average OD of inhibited wells) / (average OD of uninhibited wells).

Data processing. Each of three testing laboratories determined that test results met Quality Control requirements. Testing laboratories reported replicate OD and IgG concentration results for all well locations from specified plates to investigators at the New England Newborn Screening Program (NENSP). Transient linkages between plated specimens, test results, and demographic data were created and available to only two investigators at the NENSP (AMC and JEH) for application of inclusion and exclusion criteria followed by calculations for results' interpretation in a restricted database. A query of the restricted database yielded a de-identified coded specimen dataset with the limited data variables reported in this paper. All transient linkages to any identifiers will be irretrievably destroyed upon acceptance for publication.

Population-wide statistical model. We used dynamic (i.e., time-varying) Bayesian multilevel regression and poststratification (MRP) models to adjust seroprevalence estimates for nonrepresentative sampling by age, sex, and Massachusetts community of residence (i.e., n=351 cities or towns) and to adjust for imperfect test specificity [5] [6] [7] [8] [9] . The core approach of MRP is to estimate the outcome variable conditional on sociodemographic characteristics using a nonrepresentative data set, and then project these estimates onto a representative population of interest [5, [7] [8] [9] [10] [11] . MRP models additionally enable estimation of longitudinal seroprevalence trends at granular geographic levels, such as communities within Massachusetts. Estimation consists of two steps: first, we fit a time-varying Bayesian multilevel logistic regression model to predict serostatus conditional on age category and community random effects [10] . We used two types of time-varying functions: we primarily assessed estimates from a model grouping data by month, but we also fit a generalized additive model which modeled time continuously M a n u s c r i p t [8] . We then post-stratified the seroprevalence estimates over time using census data to individual communities and to the statewide population. In the monthly model, we also accounted for imperfect test specificity by allowing for measurement error when collecting data from true seronegatives [9] . Additional model details can be found in the Supplementary Methods.

To identify community-level factors associated with seropositivity, we fit a logistic regression model pooling data from the last four months (September through December of 2020, corresponding to the height of seropositivity). We included fixed effects for multiple demographic factors from the 2015-2019 5-year American Census Survey (Supplementary We first measured seropositive rates from this population of 1,817 DBS, assuming that their collection significantly pre-dated the COVID-19 pandemic. Each of the three testing labs received punches from the same 288 specimens punched across 4 plates. Figure 1 shows the individual [IgG] results of the anonymized specimens, the positive controls, and diluent controls by plate and by testing laboratory. The low positive controls showed IgG concentrations significantly above the mean of the tested specimens and all above the values for the tested specimens.

Among the 1,817 presumed seronegative specimens from March 2019, 7 (0.39%) were seropositive for SARS-CoV-2. Among the 72,117 study specimens, 1,261 (1.75% statewide) were seropositive; 45 seropositives were from November and December 2019. We investigated the likelihood that these early seropositive values were false positives using an inhibition assay. For comparison, of the 29 assayed seropositive specimens from July 2020, the average inhibition was 57% (confidence interval [48, 66]; minimum 22%). Of the available 45 specimens from November and December 2019, the average inhibition was 1.45% (confidence interval [1.34, 1.56]), confirming that most seropositives from 2019 were false positives. Only 3 of the 45 specimens from 2019 showed notable inhibition (18%, 27%, and 36%). The difference in the positive predictive values between late 2019 and July 2020 arises because the "cut-off" to define a positive interpretation was statistically defined (using standard deviations) by results of negative specimens on a plate-by-plate basis (the two-cycle algorithm attempts to remove potential positives when defining the final SD). This algorithm is M a n u s c r i p t expected (and indeed must by its design) define the highest values as "positives" even in a population where there are no true positives (e.g., as in Figure 1 ).

We projected the NBS seroprevalence results statewide and to Massachusetts cities and towns using multilevel regression and poststratification (MRP) and additionally accounted for imperfect test specificity. MRP enables estimation of seroprevalence at granular geographic levels and addresses non-representative sampling, which is a challenge for the NBS cohort since there are sampling biases by sex, age group, and geography relative to the overall Massachusetts population ( Supplementary Figures 1 and 2) . Statewide monthly seroprevalence in early November 2019 was estimated to be 0.03% with a 90% credible interval (CI) of 0.00% to 0.11% and remained low until May 2020 (Figure 2 ). In May 2020, seroprevalence rose to 1.47% (90% CI [1.00, 2.13]) following sustained SARS-CoV-2 transmission in the spring, and plateaued at approximately 2% from July onwards, reflecting decreased transmission in the summer months due to lockdowns, mask wearing, and other factors [13, 14] . The estimate for seroprevalence for Finally, we sought to understand community-level factors associated with increased seropositivity by fitting a multivariate model that included 14 sociodemographic variables using data from the last four months of 2020. These variables spanned population size and density, race and ethnicity, housing, education, and socioeconomic status (Supplementary Table 2 ). We calculated 90% credible intervals -representing the most plausible range of values -for the 14 estimated coefficients of association between each variable and seropositivity. The percent of the community that was non-Hispanic Black was the only variable with a 90% credible interval that excluded 0 (Table 1) ; the mean of the posterior distribution for this variable was 0.024, indicating that a 10% increase in the percent of a community that was non-Hispanic Black was associated with 27% higher odds of seropositivity, adjusting for all other included variables.

The association of percent non-Hispanic Black and percent Hispanic or Latino with increased seropositivity was driven, in part, by several cities and towns, including Brockton, Springfield, Everett, Chelsea, Lynn, and Lawrence ( Figure 5 ). We also calculated the probability of a coefficient being greater or less than zero for the 14 coefficients: percent non-Hispanic Black and percent without insurance coverage had a 90% or higher probability of being greater than 0, whereas average household size, median age, and population density had a 90% or higher probability of being less than 0. These results suggest several additional sociodemographic variables that warrant further study to characterize association with seropositivity (Supplementary Figure 6 ).

Understanding the cumulative incidence of SARS-CoV-2 is essential for setting public health policies and guiding vaccine rollouts, but the cumulative incidence for states and their cities and towns is still largely unknown because of inadequate testing and a lack of representative serosurveys. In Massachusetts, we leveraged the knowledge base and repository of our NBS program for the generation of a readily accessible, retrospective, and de-identifiable source of maternal antibodies that can inform SARS-CoV-2 seroprevalence. The strengths of this approach are multifaceted: the A c c e p t e d M a n u s c r i p t study cohort is free of biases arising from test-seeking behaviors, test availability, and symptom presence, (child-bearing women were included in the study because they had given birth, not because they were thought to have been exposed to SARS-CoV-2) [17] . The specimens and demographic data are retrospectively available for public health purposes. The key idea of our study is that by using DBS as the primary data source, we can estimate longitudinal trends in seroprevalence in childbearing women and then project these results to the population at large using statistical methods.

We analyzed data from 72,117 DBS collected across Massachusetts from November 2019 through 2020 and estimated seroprevalence using multilevel regression and poststratification (MRP), which is a Bayesian statistical method used for generalizing survey results and has been increasingly applied to epidemiological studies of SARS-CoV-2 [6, 8, 9, 18] . We found that longitudinal trends statewide and for selected cities and towns were qualitatively similar, with a rise in seropositivity in April 2020 followed by a plateau. The estimated seroprevalence levels had good concordance with cumulative incidence estimated by MAVEN case [15] data, MWRA wastewater surveillance data [16] , and other serological surveys (Supplementary Table 3 ), until the observed resurgence of transmission toward the end of 2020. While sampling into 2021 will be necessary to fully understand the extent to which these data sources diverge, one key contributing factor could be changing behaviors of pregnant women over time. We also found evidence that community percent non-Hispanic Black was the sociodemographic variable most associated with increased seroprevalence levels, in line with other epidemiological studies [19] [20] [21] [22] . These results underscore the importance of continuing equity and outreach initiatives for minority communities that were most affected by the initial epidemic wave of SARS-CoV-2.

Our findings are subject to at least several limitations and biases. As noted, selection bias could arise because fundamental risk differences between pregnant women and the general population are not accounted for in our statistical model. The direction and causes of this potential bias vary: pregnant women could have less exposure to SARS-CoV-2 due to behavioral choices or sociodemographic characteristics, but increased biological susceptibility due to immune weakening. Nonetheless, combined estimates from cohorts with clear selection biases, such as blood donors or healthy volunteers, can still meaningfully inform seroprevalence estimates in the general population [17, [23] [24] [25] . Second, misclassification bias can occur due to imperfect test specificity and sensitivity. We have estimated specificity using an early pre-pandemic ( By assessing the distribution of maternal antibodies to SARS-CoV-2 statewide and over time, our study provides a strategy for the systematic evaluation and estimation of population-wide cumulative incidence of SARS-CoV-2. Our study was conducted prior to emergency use authorization of COVID-19 vaccines. Conduct of seroprevalence studies following widespread use of vaccines would require modification of the assay to detect IgG antibodies specific to gene products (e.g., nucleocapsid protein) not expressed in the vaccine. Our approach -leveraging an easily stored and often readily available data source -may be most useful for informing cumulative incidence estimates in areas where widespread infection testing is still unavailable or remains heavily biased [17] . Prospective use of NBS-based estimates of exposure for ongoing policy development would require the more typical same-day turnaround time of clinically-based NBS programs. M a n u s c r i p t Table 2 . Posterior distribution summaries for the community-level multivariate association of demographic characteristics with seroprevalence. † indicates either P(X > 0) or P(X < 0) is 90% or higher and * indicates that the 90% credible interval excludes 0.

M a n u s c r i p t Comparison of MRP seroprevalence estimates with SARS-CoV-2 surveillance data from reported cases and wastewater testing. a) Statewide longitudinal seroprevalence trend estimated from newborn screening samples (blue) overlaid with cumulative incidence from MAVEN epidemiological surveillance data (orange). b) Seroprevalence trends for six cities and towns (blue) overlaid with MAVEN cumulative incidence (orange). c) Seroprevalence trend for the northern MWRA region (blue) versus cumulative RNA copies per mL from wastewater SARS-CoV-2 testing for the same region (pink). In all subpanels, the blue error bars depict the 90% credible interval for seroprevalence, and seroprevalence data are shifted backwards by three weeks to match the timing of surveillance data. 

Seroprevalence of human immunodeficiency virus among childbearing women. Estimation by testing samples of blood from newborns

Prevalence of HIV infection in childbearing women in the United States. Surveillance using newborn blood samples

A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction

SARS-CoV-2-specific ELISA development

Bayesian Multilevel Estimation with Poststratification: State-Level Estimates from National Polls

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors

Forecasting elections with nonrepresentative polls

results from the ONS Coronavirus Infection Survey

Bayesian analysis of tests with unknown specificity and sensitivity

Using multilevel regression and poststratification to estimate dynamic public opinion

An Introduction to Multilevel Regression and Post-Stratification for Estimating Constituency Opinion

Temperature and population density influence SARS-CoV-2 transmission in the absence of nonpharmaceutical interventions

Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe

Infectious disease surveillance in the 21st century: an integrated web-based surveillance and case management system

Wastewater COVID-19 Tracking. Available at

Newborn Dried Blood Spots for Serologic Surveys of COVID-19

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

White Counties Stand Apart: The Primacy of Residential Segregation in COVID-19 and HIV Diagnoses

Assessing differential impacts of COVID-19 on black communities

Variation in racial/ethnic disparities in COVID-19 mortality by age in the United States: A cross-sectional study

Revealing the unequal burden of COVID-19 by income, race/ethnicity, and household crowding: US county vs ZIP code analyses

Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and "Reopening

Low prevalence of antibodies against SARS-CoV-2 among voluntary blood donors in Guangzhou

Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys

We are grateful to Lisa Cavacini PhD, Mass Biologics, UMass Chan Medical School, for providing the CR3022 Mab and Shen Kuang, PhD, Program in Molecular Medicine, T.H. Chan School of Medicine, UMass Chan Medical School for providing RBD protein. We are additionally grateful to Megan Hatch, Lori Chou, Shauna Onofrey, Melody Rush, Arthur Benjamin, Deborah Britton, and the newborn heel stick specimen processing team for laboratory and analytical support throughout the project. Finally, we would like to thank our dear friend and mentor, Dr. George F Grady, for his encouragement on this project. Moderna Therapeutics (clinical trials); consulting fees from Gilead; participation on a DSMB for the Tatelo Study (NIH-funded) and received no compensation, and participation on Duke CFAR (NIH) and Boston University CTSI (NIH); and no compensation for Management Sciences for Health Board of Directors. YG reports grant from Pfizer for unrelated research and consulting fees from GSK and Quidel for unrelated topics. E.g., collected from patient's parent or sibling, collected from patient to monitor treatment **** Unsatisfactory includes conventional QC issues: poor soak, scratched/abraded, improperly dried, layered/clotted, contaminated/diluted, QNS, no blood, no demographics

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t